This activity is provided by Med Learning Group.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Copyright © 2019 Med Learning Group. Built by Divigner. All Rights Reserved.
The most recent GOLD recommendations assign patients’ COPD symptoms and exacerbation risk across three groups: A, B and E. Once a group is assigned, initial pharmacologic treatment is described for each individual group. The treatment of patients in Group A has not changed. In contrast, for patients in Group B, a dual long-acting bronchodilator combination (b2 adrenergic [LABA] and an anti-muscarinic [LAMA] bronchodilator) is now recommended since dual therapy is more effective than monotherapy, with similar side effects. For patients in Group E, LAMA + LABA is also the recommended initial therapy, except for patients with blood eosinophils > 300 cells/μL, in whom starting triple therapy (LABA + LAMA + ICS) can be considered. The important predictive role of the blood eosinophil count, exacerbation risk, and response to ICS are discussed below.1
This activity is provided by Med Learning Group.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Copyright © 2019 Med Learning Group. Built by Divigner. All Rights Reserved.